Correspondingly, whether patients with previous exposure to a DLL3-targeted therapy may benefit from rechallenge with a DLL3-targeted therapy of a different class at progression, and optimal sequencing of these therapies, remains unclear, as resistance could proceed through selection for DLL3-negative subclones, or other tumor-intrinsic or extrinsic mechanisms. Here, DLL3 is linked to neoplasm.